Autorinnen und Autoren des Paul-Ehrlich-Instituts sind durch Fettdruck kenntlich gemacht. Wenn Online-Abstracts oder Volltexte zu den Publikationen verfügbar sind, so sind diese verlinkt.
Schambach A, Buchholz CJ, Torres-Ruiz R, Cichutek K, Morgan M, Trapani I, Büning H (2023): A new age of precision gene therapy.
Lancet Nov 22 [Epub ahead of print].
Online-Abstract
Miranda-García MA, Hoffelner M, Stoll H, Ruhaltinger D, Cichutek K, Siedler A, Bekeredjian-Ding I (2022): A 5-year look-back at the notification and management of vaccine supply shortages in Germany.
Euro Surveill 27: 2100167.
Text
Theuerkauf SA, Michels A, Riechert V, Maier TJ, Flory E, Cichutek K, Buchholz CJ (2021): Quantitative Assays Reveal Cell Fusion at Minimal Levels of SARS-CoV-2 Spike Protein and Fusion-from-Without.
iScience 24: 102170.
Online-Abstract
Wagner R, Hildt E, Grabski E, Sun Y, Meyer H, Lommel A, Keller-Stanislawski B, Müller-Berghaus J, Cichutek K (2021): Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks.
Vaccines (Basel) 9: 747.
Text
Patasic L, Seifried J, Bezler V, Kaljanac M, Schneider IC, Schmitz H, Tondera C, Hartmann J, Hombach A, Buchholz CJ, Abken H, König R, Cichutek K (2020): Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4 + T cells to reduce the latent HIV + cell reservoir.
Med Microbiol Immunol 209: 681-691.
Online-Abstract
Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, Carson JL, Cichutek K, De Buck E, Devine D, Fergusson D, Folléa G, French C, Frey KP, Gammon R, Levy JH, Murphy MF, Ozier Y, Pavenski K, So-Osman C, Tiberghien P, Volmin J, Waters JH, Wood EM, Seifried E, ICC PBM Frankfurt 2018 Group (2019): Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.
JAMA 321: 983-997.
Online-Abstract
Miranda-Garcia MA, Cichutek K, Bekeredjian-Ding I (2017): Wie lange bleibt der Kühlschrank leer? Das Paul-Ehrlich-Institut analysierte die Lieferengpässe bei Reiseimpfstoffen.
Dtsch Apoth Ztg 157: 24-29.
Text
Miranda-Garcia MA, Götz KB, Ruhaltinger D, Cichutek K, Bekeredjian-Ding I (2017): Lieferengpässe von Impfstoffen: Einblick in Zahlen und Hintergründe.
Dtsch Arztebl 114: A-844 / B-714 / C-700.
Text
Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S (2016): Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.
Virology 489: 1-11.
Online-Abstract
Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD (2016): Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.
Mol Ther Oncolytics 3: 16003.
Text
Marino D, Perković M, Hain A, Jaguva Vasudevan AA, Hofmann H, Hanschmann KM, Mühlebach MD, Schumann GG, König R, Cichutek K, Häussinger D, Münk C (2016): APOBEC4 Enhances the Replication of HIV-1.
PLOS ONE 11: e0155422.
Text
Zhang Z, Gu Q, Jaguva Vasudevan AA, Jeyaraj M, Schmidt S, Zielonka J, Perkovic M, Heckel JO, Cichutek K, Häussinger D, Smits SH, Münk C (2016): Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
J Virol 90: 10193-10208.
Online-Abstract
Zhang Z, Gu Q, Jaguva Vasudevan AA, Hain A, Kloke BP, Hasheminasab S, Mulnaes D, Sato K, Cichutek K, Häussinger D, Bravo IG, Smits SH, Gohlke H, Münk C (2016): Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors.
Retrovirology 13: 46.
Text
Cichutek K, Scherer J, Conrad C, Heininger U, Spiess H: Historie und Zukunft von Schutzimpfungen.
In: Spiess H, Heininger U, Jilg W (Hrsg.), Impfkompendium. 8., vollst. überarb. Aufl., Stuttgart [u.a.]: Thieme, 2015. S. 28-34, ISBN 978-3-13-498908-3
Hinz T, Cichutek K (2015): Special aspects concerning the marketing authorization of RNA-based medicines.
Pharmakon 3: 309-316.
Online-Abstract
Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Shams Eldin H, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD (2015): A highly immunogenic and protective MERS-Coronavirus vaccine based on recombinant MV vaccine platform.
J Virol 89: 11654-11667.
Online-Abstract
Pfleiderer M, Cichutek K: Herstellung und Prüfung von Impfstoffen.
In: Spiess H, Heininger U, Jilg W (Hrsg.), Impfkompendium. 8., vollst. überarb. Aufl., Stuttgart [u.a.]: Thieme, 2015. S. 44-55, ISBN 978-3-13-498908-3
Weiss K, Gerstenberger J, Salzig D, Mühlebach MD, Cichutek K, Pörtner R, Czermak P (2015): Oncolytic measles viruses produced at different scales under serum-free conditions.
Eng Life Sci 15: 425-436.
Online-Abstract
Blochmann R, Curths C, Coulibaly C, Cichutek K, Kurth R, Norley S, Bannert N, Fiebig U (2014): A novel small animal model to study the replication of simian foamy virus in vivo.
Virology 448: 65-73.
Online-Abstract
Heidmeier S, Hanauer JR, Friedrich K, Prüfer S, Schneider IC, Buchholz CJ, Cichutek K, Mühlebach MD (2014): A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains.
Virus Res 180: 43-48.
Online-Abstract
Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A, Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Sohn Y, Wood D (2013): A global regulatory science agenda for vaccines.
Vaccine 31: B163-B175.
Online-Abstract
Friedrich K, Hanauer JRH, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD (2013): DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.
Mol Ther 21: 849-859.
Online-Abstract
Jaguva Vasudevan AA, Perkovic M, Bulliard Y, Cichutek K, Trono D, Häussinger D, Münk C (2013): Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3G.
J Virol 87: 9030-9040.
Online-Abstract
Langer B, Renner M, Scherer J, Schüle S, Cichutek K (2013): Safety assessment of biolistic DNA vaccination.
Methods Mol Biol 940: 371-388.
Online-Abstract
Müller-Berghaus J, Volkers P, Scherer J, Cichutek K (2013): Besonderheit bei der Regulierung biologischer Arzneimittel in der individualisierten Medizin.
Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 56: 1538-1544.
Text
Scherer J, Seitz R, Cichutek K (2013): Autologe Zellpräparate: Wenn Ärzte "Arzneimittel" im OP oder am Krankenbett herstellen.
Dtsch Arztebl 110: A872-A876.
Text
Weiss K, Salzig D, Röder Y, Gerstenberger J, Mühlebach MD, Cichutek K, Pörtner R, Czermak P (2013): Influence of Process Conditions on Measles Virus Stability.
Am J Biochem Biotechnol 9: 243-254.
Online-Abstract
Kopietz F, Jaguva Vasudevan AA, Krämer M, Muckenfuss H, Sanzenbacher R, Cichutek K, Flory E, Münk C (2012): Interaction of human immunodeficiency virus type 1 Vif with APOBEC3G is not dependent on serine/threonine phosphorylation status.
J Gen Virol 93: 2425-2430.
Online-Abstract
Schweizer M, Cichutek K: Introduction.
In: Cohen-Hagenauer O (Hrsg.), Clinical Gene Transfer - State Of The Art (The CliniBook). Paris: EDK, 2012. S. 127-128
Schweizer M, Cichutek K: Development of SIVsmmPBj vectors for gene transfer into myeloid cells.
In: Cohen-Hagenauer O (Hrsg.), Clinical Gene Transfer - State Of The Art (The CliniBook). Paris: EDK, 2012. S. 134-138
Weiss K, Salzig D, Mühlebach MD, Cichutek K, Pförtner R, Czermak P (2012): Key Parameters of Measles Virus Production for Oncolytic Virotherapy.
Am J Biochem Biotechnol 8: 81-98.
Online-Abstract
Cichutek K, Scherer J, Heininger U, Spiess H: Historie und Zukunft von Schutzimpfungen.
In: Spiess H, Heininger U, Jilg W (Hrsg.), Impfkompendium. 7., vollst. überarb. und erw. Aufl., Stuttgart: Thieme, 2011. S. 1-7
Dörrschuck E, Fischer N, Bravo IB, Hanschmann KM, Kuiper H, Spötter A, Möller R, Cichutek K, Münk C, Tönjes RR (2011): Restriction of Porcine Endogenous Retrovirus by Porcine APOBEC3 Cytidine Deaminases.
J Virol 85: 3842-3857.
Online-Abstract
Grabski E, Waibler Z, Schüle S, Kloke BP, Sender LY, Panitz S, Cichutek K, Schweizer M, Kalinke U (2011): Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.
Mol Biotechnol 47: 262-269.
Online-Abstract
Langer B, Cichutek K (2011): Arzneimittel für neuartige Therapien: Therapeutische und regulatorische Aspekte.
Internistische Praxis 4: 845-854.
Langer B, Cichutek K (2011): Klinische Anwendung der Gentherapie.
Pharm Unserer Zeit 3: 254-262.
Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VHJ, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray Jr PB, Cichutek K, von Messling V, Lopez M, Cattaneo R (2011): Adherens junction protein nectin-4 (PVRL4) is the epithelial receptor for measles virus.
Nature 480: 530-533.
Text
Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ (2011): DARPins: an efficient targeting domain for lentiviral vectors.
Mol Ther 19: 686-693.
Online-Abstract
Pfleiderer M, Cichutek K: Herstellung und Prüfung von Impfstoffen.
In: Spiess H, Heininger U, Jilg W (Hrsg.), Impfkompendium. 7., vollst. überarb. und erw. Aufl., Stuttgart: Thieme, 2011. S. 16-28
Schaser T, Wrede C, Duerner L, Sliva K, Cichutek K, Schnierle B, Buchholz CJ (2011): RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.
Gene Ther 18: 953-960.
Online-Abstract
Schneider IC, Eckhardt M, Brynza J, Collins MK, Cichutek K, Buchholz CJ (2011): Escape from R-peptide deletion in a γ-retrovirus.
Virology 2: 85-92.
Online-Abstract
Tschulena U, Sanzenbacher R, Mühlebach MD, Berger A, Münch J, Schindler M, Kirchhoff F, Plesker R, Coulibaly C, Panitz S, Prüfer S, Muckenfuss H, Hamdorf M, Schweitzer M, Cichutek K, Flory E (2011): Mutation of a diacidic motif in SIV-PBj Nef impairs T-cell activation and enteropathic disease.
Retrovirology 8: 14.
Online-Abstract
Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, Schneider IC, Muench RC, Petznek H, Kontermann RE, Koehl U, Johnston ICD, Keinänen K, Müller UC, Hohenadl C, Monyer H, Cichutek K, Buchholz CJ (2010): Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.
Nat Methods 7: 929-935.
Online-Abstract
Berger A, Münk C, Schweizer M, Cichutek K, Schüle S, Flory E (2010): Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes.
J Biol Chem 285: 12248-54.
Online-Abstract
Cichutek K, Granzer U (2010): Der Rahmen ist gesetzt: Fortschritte bei Gen-, Zelltherapeutika und Tissue Engineering-Arzneimitteln.
Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz 53: 1-3.
Online-Abstract
Text
Cohen-Haguenauer O, Creff N, Cruz P, Tunc C, Aiuti A, Baum C, Bosch F, Blomberg P, Cichutek K, Collins M, Danos O, Dehaut F, Federspiel M, Galun E, Garritsen H, Hauser H, Hildebrandt M, Klatzmann D, Merten OW, Montini E, O'Brien T, Panet A, Rasooly L, Scherman D, Schmidt M, Schweizer M, Tiberghien P, Vandendriessche T, Ziehr H, Ylä-Herttuala S, von Kalle C, Gahrton G, Carrondo M (2010): Relevance of an academic GMP Pan-European vector infra-structure (PEVI).
Curr Gene Ther 10: 414-422.
Online-Abstract
Kloke BP, Schüle S, Mühlebach MD, Wolfrum N, Cichutek K, Schweizer M (2010): Functional HIV-2- and SIVsmmPBj- derived lentiviral vectors generated by a novel polymerase chain reaction-based approach.
J Gene Med 12: 446-452.
Online-Abstract
Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KMO, Cattaneo R, Bitzer M, Lauer UM, Cichutek K, Buchholz CJ (2010): Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Cancer Res 70: 7620-7629.
Online-Abstract
Mühlebach MD, Schüle S, Gerlach N, Schweizer M, Buchholz CJ, Hohenadl C, Cichutek K: Gammaretroviral and Lentiviral Vectors for Gene Delivery.
In: Kurth R, Bannert N (Hrsg.), Retroviruses: Molecular Biology, Genomics and Pathogenesis. Norfolk: Caister Academic Press, 2010. 347-370 ISBN 9781904455554
Perkovic M, Norley S, Sanzenbacher R, Battenberg M, Panitz S, Coulibaly C, Flory E, Siegismund C, Münk C, Cichutek K (2010): SIVagm containing the SHIV89.6P Envelope gene replicates poorly and is non-pathogenic.
Virology 399: 87-97.
Online-Abstract
Seitz R, Heiden M, Funk M, Keller-Stanislawski B, Cichutek K (2010): Die Rolle des Paul-Ehrlich-Instituts im Transfusionswesen.
Hämotherapie 14: 69-73.
Straßburger J, Meilicke R, Cichutek K (2010): Arzneimittelrechtliche Anforderungen an Arzneimittel für neuartige Therapien aus humanen Pankreata.
MedR 28: 835-841.
Buchholz CJ, Mühlebach MD, Cichutek K (2009): Lentiviral vectors with measles virus glycoproteins – dream team for gene transfer?.
Trends Biotechnol 27: 259-265.
Online-Abstract
Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R, Cichutek K, Buchholz CJ (2009): Pseudotyping lentiviral vectors with the wildtype measles virus glycoproteins improves titer and selectivity.
Gene Ther 16: 700-705.
Online-Abstract
Perkovic M, Schmidt S, Marino D, Russell RA, Stauch B, Hofmann H, Kopietz F, Kloke BP, Zielonka J, Ströver H, Hermle J, Lindemann D, Pathak VK, Schneider G, Löchelt M, Cichutek K, Münk C (2009): Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.
J Biol Chem 284: 5819-5826.
Online-Abstract
Reinhardt J, Kretzschmar E, Cichutek K: Paul-Ehrlich-Institut : a federal research and regulatory institute with international competence for vaccines and biomedicines.
Hessen – Gateway to Contract Research in Europe: A practical Guide to Sites and Services, second edition. Wiesbaden: HA Hessen Agentur, 2009. 11-13
(Aktionslinie Hessen-Biotech 8)
Cichutek K: Gene Therapy: Achievements and Challenges.
In: Nisticò G, Papaluca-Amati M, Brasseur D (Hrsg.), Challenges in New Advanced Therapies. Rome: Exorma, 2008. 16-22. ISBN 978-88-95688-07-7
(Monograph Series Vol. 3)
Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ (2008): Targeted cell entry of lentiviral vectors.
Mol Ther 16: 1427-1436.
Online-Abstract
Münk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O'Brien SJ, Löchelt M, Yuhki N (2008): Functions, structure, and read-through alternative splicing of feline APOBEC3 genes.
Genome Biol 9: R48.
Online-Abstract
Scherer J, Hinz T, Cichutek K (2008): Trends in der Impfstoffentwicklung. DNA- und zellbasierte Impfstoffe.
Pharmazie in unserer Zeit 37: 86-92.
Online-Abstract
Schilling-Leiß D, Godehardt AW, Scherer J, Cichutek K, Tönjes RR (2008): Genehmigungsverfahren für klassische Gewebezubereitungen gemäß § 21a Arzneimittelgesetz (AMG).
Transfus Med Hemother 35: 453-462.
Online-Abstract
Sun Y, Song M, Jäger E, Schwer C, Stevanovic S, Flindt S, Karbach J, Nguyen XD, Schadendorf D, Cichutek K (2008): Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
Clin Cancer Res 14: 4306-4315.
Online-Abstract
Tönjes RR, Scherer J, Cichutek K: Regelungen des Gewebegesetzes für klassische Gewebezubereitungen und Stand der Genehmigungsverfahren gemäß § 21a Arzneimittelgesetz.
Pühler W., Middel C.-D., Hübner M. (Hrsg.), Praxisleitfaden Gewebegesetz Köln: Deutscher Ärzte-Verlag, 2008. 161-175 ISBN 978-3-7691-3377-6
Muckenfuss H, Cichutek K, Flory E (2007): Current Regulation of Advanced Therapy Medicinal Products in the European Union.
J Intern Biotechnology Law 4: 16-20.
Online-Abstract
Münk C, Zielonka J, Constabel H, Kloke BP, Rengstl B, Battenberg M, Bonci F, Pistello M, Löchelt M, Cichutek K (2007): Multiple Restrictions of Human Immunodeficiency Virus Type 1 in Feline Cells.
J Virol 81: 7048-7060.
Online-Abstract
Sanzenbacher R, Dwenger A, Schuessler-Lenz M, Cichutek K, Flory E (2007): European regulation tackles tissue engineering.
Nat Biotechnol 25: 1089-1091.
Wolfrum N, Mühlebach MD, Schüle S, Kaiser JK, Kloke BP, Cichutek K, Schweizer M (2007): Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells.
Virology 364: 330-341.
Online-Abstract
Hamdorf M, Muckenfuss H, Tschulena U, Cichutek K, Flory E (2006): An inducible T7 RNA polymerase-dependent expression system for generation of small interfering RNAs.
Mol Biotechnol 33: 13-22.
Online-Abstract
Hinz T, Buchholz CJ, van der Stappen T, Cichutek K, Kalinke U (2006): Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.
J Immunother 29: 472-476.
Online-Abstract
Merten CA, Stitz J, Braun G, Medvedovska J, Cichutek K, Buchholz CJ (2006): Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein.
Nucleic Acids Res 34: e41.
Online-Abstract
Muckenfuss H, Hamdorf M, Held U, Perkovic M, Löwer J, Cichutek K, Flory E, Schumann GG, Münk C (2006): APOBEC3 proteins inhibit human LINE-1 retrotransposition.
J Biol Chem 281: 22161-22172.
Online-Abstract
Muckenfuss H, Sanzenbacher R, Hamdorf M, Tschulena U, Avots A, Cichutek K, Flory E (2006): Interleukin-2 induction by simian immunodeficiency virus involves MAP Kinase signalling but is independent on Calcineurin/NF-AT activity.
Mol Immunol 43: 1172-1182.
Online-Abstract
Neumann J, Stitz J, König R, Seibold E, Norley S, Flory E, Cichutek K (2006): Retroviral vectors for vaccine development: Induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV(HIV-1) pseudotype vector.
J Biotechnol 124: 615-625.
Online-Abstract
Schüle S, Steidl S, Panitz S, Coulibaly C, Kalinke U, Cichutek K, Schweizer (2006): Selective gene transfer to T lymphocytes using coreceptor-specific [MLV(HIV)] pseudotype vectors in a transgenic mouse model.
Virology 351: 237-247.
Online-Abstract
Stitz J, Wolfrum N, Buchholz CJ, Cichutek K (2006): Envelope proteins of spleen necrosis virus form infectious human immunodeficiency virus type 1 pseudotype vector particles, but fail to incorporate upon substitution of the cytoplasmic domain with that of Gibbon ape leukemia virus.
J Gen Virol 87: 1577-1581.
Online-Abstract
Sun Y, Stevanovic S, Song M, Schwantes A, Kirkpatrick CJ, Schadendorf D, Cichutek K (2006): The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes.
Blood 107: 1476-1483.
Online-Abstract
Cichutek K (2005): Grundlagen der klinischen Prüfung von Arzneimitteln.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 48: 395-396.
Text
Finger C, Sun Y, Sanz L, Alvarez-Vallina L, Buchholz CJ, Cichutek K (2005): Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
Cancer Gene Therapy 12: 464-474.
Online-Abstract
Hartl I, Schneider RM, Sun Y, Medvedovska J, Chadwick MP, Russel SJ, Cichutek K, Buchholz CJ (2005): Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells.
Gene Ther 12: 918-926.
Krafft H, Cichutek K (2005): Approval of clinical trials of immunobiological medicinal products at the Paul Ehrlich Institute.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 48: 168-172.
Online-Abstract
Löchelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, Truyen U, Rösler U, Battenberg M, Saib A, Flory E, Cichutek K, Münk C (2005): The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.
Proc Natl Acad Sci Epub May 23; 102: 7982-7987.
Online-Abstract
Merten CA, Stitz J, Braun G, Poeschla EM, Cichutek K, Buchholz CJ (2005): Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles.
J Virol 79: 834-840.
Online-Abstract
Mühlebach MD, Wolfrum N, Schüle S, Tschulena U, Sanzenbacher R, Flory E, Cichutek K, Schweizer M (2005): Stable Transduction of Primary Human Monocytes by Simian Lentiviral Vector PBj.
Mol Ther 12: 1206-1216.
Nikles D, Bach P, Boller K, Merten CA, Montrasio F, Heppner FL, Aguzzi A, Cichutek K, Kalinke U, Buchholz CJ (2005): Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP.
J Virol 79: 4033-4042.
Online-Abstract
Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz CJ (2005): Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth.
Cancer Gene Ther 12: 900-912.
Online-Abstract
Urban JH, Schneider RM, Compte M, Finger C, Cichutek K, Alvarez-Vallina L, Buchholz CJ (2005): Selection of functional human antibodies from retroviral display libraries.
Nucleic Acids Res 33: e35.
Dreier G, Cichutek K (2004): Das Deutsche Register für somatische Gentransferstudien-DeReG: Einrichtung eines zentralen Registers klinischer Gentransferstudien in Deutschland.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 47: 554-558.
Online-Abstract
Text
Steidl S, Schüle S, Mühlebach MD, Stitz J, Boller K, Cichutek K, Schweizer M (2004): Genetic engineering of onco/lentivirus hybrids results in formation of infectious particles but not of replication-competent viruses.
J Gen Virol 85: 665-678.
Online-Abstract
Merten CA, Engelstaedter M, Buchholz CJ, Cichutek K (2003): Displaying epidermal growth factor on spleen necrosis virus-derived targeting vectors.
Virology 305: 106-114.
Online-Abstract
Mühlebach MD, Schmitt I, Steidl S, Stitz J, Schweizer M, Blankenstein T, Cichutek K, Uckert W (2003): Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.
J Mol Med 81: 801-810.
Online-Abstract
Schneider R, Medvedovska J, Hartl I, Voelker B, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ (2003): Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases.
Gene Ther 10: 1370-1380.
Online-Abstract
Bobkova M, Stitz J, Engelstädter M, Cichutek K, Buchholz CJ (2002): Identification of R-peptides in envelope proteins of C-type retroviruses.
J Gen Virol 83: 2241-2246.
Online-Abstract
Cohen-Haguenauer O, Rosenthal F, Gänsbacher B, Bolhuis R, Dorsch-Häsler K, Eshhar Z, Gahrton G, Hokland, Melani C, Rankin E, Thielemans K, Vile R, Zwierzina H, Cichutek K (2002): Opinion paper on the current status of the regulation of gene therapy in Europe.
Hum Gene Ther 13: 2085-2110.
König RR, Flory E, Steidl S, Neumann J, Coulibaly C, Holznagel E, Holzammer S,, Norley S, Cichutek K (2002): Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.
J Virol 76: 10627-36.
Online-Abstract
Steidl S, Stitz J, Schmitt I, König R, Flory E, Schweizer M, Cichutek K (2002): Coreceptor Switch of [MLV(SIVagm)] Pseudotype Vectors by V3-Loop exchange.
Virology Sep. 1; 300: 205-216.
Online-Abstract
Cichutek K (2001): Gentherapie: Gut' Ding will Weile haben.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 44: 1029-1030.
Online-Abstract
Text
Cichutek K: Somatische Gentherapie: Stand der klinischen Forschung und Regularien in Deutschland.
In: Eberbach W, Lange P (Hrsg.), Recht der Gentechnik und Biomedizin, Gen TR/BioMedR: EG-Recht, Gesetze, Verordnungen, Formulare, ZKBS-Empfehlungen, Beschlüsse des LAG ; Richtlinien, Empfehlungen u. Stellungnahmen von Institutionen u. Vereinigungen. Heidelberg: C.F. Müller, 2001
Cichutek K, Schweizer M, Flory E, Buchholz CJ (2001): Regulatorische Aspekte der Anwendung von Gentransfer-Arzneimitteln in der Humanmedizin.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 44: 1083-1089.
Online-Abstract
Volltext
Engelstädter M, Buchholz CJ, Bobkova M, Steidl S, Merget-Millitzer H, Willemsen RA, Stitz J, Cichutek K (2001): Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins.
Gene Ther 8: 1202-1206.
Schweizer M, Flory E, Buchholz CJ, Cichutek K (2001): Retroviral Vectors.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 44: 1038-1046.
Online-Abstract
Text
Stitz J, Mühlebach MD, Blömer U, Scherr M, Selbert M, Wehner P, Steidl S, Schmitt I, König R, Schweizer M, Cichutek K (2001): A Novel Lentivirus vector derived from apathogenic simian immunodeficiency virus.
Virology 291: 191-197.
Online-Abstract
Cichutek K (2000): DNA Vaccines: Development, Standardization and Regulation.
Intervirology 43: 331-338.
Online-Abstract
Engelstädter M, Bobkova M, Baier M, Stitz J, Holtkamp N, Chu N, Kurth R, Dornburg R, Buchholz CJ, Cichutek K (2000): Targeting human T cells by retroviral vectors displaying antibody fragments selected from a phage display library.
Hum Gene Ther 11: 293-303.
Online-Abstract
Engelstädter M, Bobkova M, Buchholz CJ, Cichutek K (2000): Herstellung retroviraler Zelltargeting-Vektoren.
BIOforum 23: 96-98.
Stitz J, Buchholz CJ, Cichutek K (2000): MLV-derived retroviral pseudotype vectors.
Gene Therapy and Regulation 1: 177-192.
Online-Abstract
Stitz J, Buchholz CJ, Engelstädter M, Uckert W, Blömer U, Schmitt I, Cichutek K (2000): Lentiviral vectors pseudotyped with envelope glycoproteins derived from Gibbon ape leukaemia virus and murine virus 10A1.
Virology 273: 16-20.
Online-Abstract
Stitz J, Steidl S, Merget-Millitzer H, König R, Müller P, Nocken F, Engelstädter M, Bobkova M, Buchholz CJ, Kurth R, Cichutek K (2000): MLV-derived retroviral vectors selective for CD4 expressing cells and are resistant to neutralisation by sera from HIV-infected patients.
Virology 267: 229-236.
Online-Abstract
Buchholz CJ, Stitz J, Cichutek K (1999): Retroviral Cell Targeting Vectors.
Curr Opin Mol Ther 1: 613-621.
Online-Abstract
Stitz J, Selbert M, Wehner P, Müller P, König R, Engelstädter M, Bobkova M, Steidl S, Schmitt I, Buchholz C, Kurth R, Cichutek K (1999): Lentiviral vectors derived from apathogenic SIVagm Deutscher AIDS-Kongreß, Essen, 02.–6.06.99.
Eur J Med Res 4: 7.
Müller P, Dittmar MT, Beer B, König R, Plesker R, Norley S, Kurth R, Cichutek K (1998): Increased serum and mRNA levels of MIP-1b and RANTES associated with elevated levels of activated CD8+CD38+ T-cells in HIV-1 infected individuals.
Intervirology.
Stitz J, Müller P, Cichutek K (1998): High-titer retroviral pseudotype vectors for specific targeting of human CD4-positive cells.
Biogenic Amines 14: 407-424.
Wagener S, Dittmar MT, Beer B, König R, Plesker R, Norley S, Kurth R, Cichutek K (1998): The U3 Promoter and the nef Gene of Simian Immunodeficiency Virus (SIV) smmPBj1.9 Do Not Confer Acute Pathogenicity upon SIVagm.
J. Virol 72: 3446-3450.
Merget-Millitzer H, Müller P, Engelstädter M, Wagener S, Cichutek K (1997): HIV and AIDS: Implications of the genetic variability of HIV for pathogenesis and epidemiology.
Biotest Bulletin 5: 245-259.
Schnierle BS, Stitz J, Nocken F, Merget-Millitzer H, Engelstädter M, Bosch V, Kurth R, Groner B, Cichutek K (1997): Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4 expressing cells.
PNAS 94: 8640-8645.
Online-Abstract
Beer B, Norley S, Cichutek K, Kurth R (1996): Control of Initial Viraemia Coincides with Neutralizing Antibody Response after SIVmac Infection of Rhesus Macaques.
AIDS 10: 681-682.
Dittmar MT, Wagener S, Fultz P, Kurth R, Cichutek K (1996): An in vitro assay for the acute pathogenicity of immunodeficiency viruses.
Dev. Biol. Stand. 88: 167-174.
Jin M, Ido E, Kuwata T, Igarashi T, Cichutek K, Kurth R, Miura T, Enose Y, Chen J, Hayami M (1996): Replication and cytopathogenicity of HIV-1/SIVagm3 chimeric viruses in human and monkey cells: The 5´-half of the HIV-1 genome is responsible for the viral cytopathogenicity.
J. Gen.Virol. 77: 2427-2431.
Online-Abstract
Merget-Millitzer H, Müller P, Engelstädter M, Wagener S, Cichutek K (1996): HIV and AIDS: Implications of the genetic variability of HIV for pathogenesis and epidemiology.
.
Wagener S, Norley S, zur Megede J, Kurth R, Cichutek K (1996): Induction of antibodies against SIV antigens after intramuscular nucleic acid inoculation using complex expression constructs.
J. Biotechnol. 44: 59-65.
Online-Abstract
